Identification of Novel Isoforms of a Gene and Their Potential Utility in Diagnostic and Therapeutic Applications

Web Published:
11/1/2013
Description:

Identification of Novel Isoforms of a Gene and

Their Potential Utility in Diagnostic and Therapeutic Applications in Diseases of

Cellular Motility, Migration, and/or Invasion

 

Princeton Docket # 13-2929-1

High throughput sequencing approaches have revealed increased complexity of the transcriptome. For example, one gene may give rise to multiple mRNAs and peptides as a result of alternative splicing and/or polyadenylation events. Researchers in the Department of Molecular Biology, Princeton University, have identified a gene from which two distinct mRNAs are transcribed. These two isoforms possess opposing functions. Namely, a short mRNA isoform, which is not membrane-bound, promotes cell invasion and motility, and a long mRNA isoform inhibits invasion and motility. Determining the expression levels of these isoforms may be a useful diagnostic and prognostic tool in any pathological state characterized by a defect in cellular motility, migration and/or invasion. Furthermore, manipulating the balance of these two isoforms may prove to be a useful therapeutic tool.

 

Applications:   

Diagnostic and/or prognostic indicator for research in clinical conditions such as:

·         Cancer

·         Rheumatoid Arthritis

·         Osteoarthritis

·         Fibrosis

·         Scleroderma

·         Congenital defects, e.g., during brain development

 

Advantages:

The short mRNA isoform:

·         May alter the migratory behavior of a cell

·         Is not membrane-bound

·         Promotes cell invasion and motility

 

The long mRNA isoform inhibits invasion and motility.

Inventors

 

Hilary Coller is Associate Professor at UCLA. The Coller lab uses genomic approaches to gain insight into cell cycle control in normal tissues and cancer. Because uncontrolled cell division is so dangerous for an organism, the well-behaved cell must know not only when to divide, but crucially when not to. Shutting down cell division prevents tumors and maintains the proper form of tissues. Many cells, though, including fibroblasts, must also retain the ability to start dividing again when conditions are right, when the organism must grow, or a damaged tissue must be repaired. A cell in such a temporary, non-dividing state is said to be quiescent. Signals that send a cell into quiescence include loss of contact with the underlying surface, too much contact with neighboring cells, and not receiving specific growth factors from the surroundings.

 

David Corney is a Visiting Postdoctoral Research Associate, Lewis-Sigler Institute for Integrative Genomics at Princeton University. Dr. Corney obtained his Ph.D. at Cornell University, where he identified tumor suppressive microRNAs regulated by the p53 tumor suppressor gene. During postdoctoral studies at Stanford University he studied the role of microRNAs in colorectal cancer and used RNA-seq to characterize the transcriptomes of proliferative and quiescent intestinal stem cells. Working together with Dr. Coller at Princeton University and UCLA he is using RNA-seq to characterize the quiescent fibroblast transcriptome and determine the functional role of alternative polyadenylation events.

 

 Intellectual Property Status

Patent protection is pending.

Princeton is seeking to identify appropriate partners for the further development and commercialization of this technology.

Contact

Laurie Tzodikov
Princeton University Office of Technology Licensing • (609) 258-7256•
tzodikov@princeton.edu

Laurie Bagley
Princeton University Office of Technology Licensing • (609) 258-5579•
lbagley@princeton.edu

 

 

 

 

 

 

 

Patent Information:
For Information, Contact:
Laurie Tzodikov
Licensing Associates
Princeton University
tzodikov@Princeton.EDU
Inventors:
Hilary Coller
David Corney
Keywords:
biomarker/diagnostic
cancer/oncology
life science research tools
therapeutic